久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

上海非利加實業(yè)有限公司Logo

熱門詞: 進(jìn)口電動溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動高溫調(diào)節(jié)閥-德國進(jìn)口電動高溫法蘭調(diào)節(jié)閥進(jìn)口電動蒸汽調(diào)節(jié)閥-德國進(jìn)口電動蒸汽調(diào)節(jié)閥

當(dāng)前位置: 首頁 > 所有品牌 > MannKind
MannKind
MannKind MannKind

美國MannKind Corporation?
胰島素吸入設(shè)備生產(chǎn)商MannKind Corp


MannKind Corporation (Nasdaq:MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, AFREZZA?, is an ultra rapid-acting insulin. We have submitted a new drug application to the FDA requesting approval of AFREZZA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.

The pharmacokinetic profile of AFREZZA sets it apart from all other insulin products. AFREZZA particles dissolve upon contact with the lung surface, releasing insulin that rapidly enters the bloodstream. It achieves peak insulin levels within 12-14 minutes of administration, which more closely mimics the natural release of insulin than any other insulin preparation. In our clinical trials, we have observed that patients using the AFREZZA have achieved significant reductions in post-meal glucose excursions and significant improvements in overall glucose control, as measured in AIC levels, without the weight gain typically associated with insulin therapy.

AFREZZA utilizes our proprietary Technosphere? formulation technology, which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded. With AFREZZA, we load human insulin onto the Technosphere particles; however, this technology is not limited to insulin delivery. We believe it represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Beyond convenience, we believe the key advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration.

In addition to our Technosphere platform, we are developing therapies for the treatment of different types of cancer. Our cancer immunotherapy program is advancing to Phase 2 studies in patients with advanced melanoma and we are conducting preclinical studies of a drug candidate for the treatment of certain malignancies and inflammatory diseases.
?

關(guān)于我們客戶服務(wù)產(chǎn)品分類法律聲明
主站蜘蛛池模板: 欧美性第一页 | 日韩毛片大全 | 欧美亚洲国产一区 | 国产精品久久久久久一区二区 | 日日综合 | 久久成人国产精品一区二区 | 伊人中文字幕 | 夜色毛片永久免费 | 国产欧美日韩精品在钱 | 国产在线看不卡一区二区 | 日韩最新视频一区二区三 | 中文字幕有码在线播放 | 日本成人一区 | 欧美第一页在线 | 一区二区三区视频在线播放 | 日韩一级精品视频在线观看 | 伊人久久精品久久亚洲一区 | 亚洲精品国产第七页在线 | 欧美 日韩 中文 | 欧美第一区 | 黄色a级毛片 | 国产精品亚洲精品日韩动图 | 久久www免费人成精品香蕉 | 欧美性另类69xxx | 一区二区三区在线视频观看 | 久久精品国产一区二区三区日韩 | 久久亚洲精品国产精品777777 | 欧美高清不卡 | 久久不射电影网 | 国产一区二区三区欧美 | 亚洲 另类 在线 欧美 制服 | 亚洲欧美日韩高清一区二区三区 | 亚洲电影中文字幕 | 亚欧色 | 国产a国产片 | 久久国语精品 | 亚洲国产成人精品一区二区三区 | 国内精品久久久久久久aa护士 | 在线精品欧美日韩 | 欧美在线视频网站 | 日韩欧美国产另类 |